MediWound (MDWD) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed MediWound (MDWD) over the past year, gaining 97.6% versus a loss of 29.5%. Over five years, OBIO leads with a -41.8% price change compared with -48.0% for MDWD. Orchestra BioMed is the larger company by market cap ($357.6 million vs $161.9 million), about 2.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDWD | OBIO |
|---|---|---|
| Share price | $12.54 | $5.95 |
| Market cap | $161.89M | $357.63M |
| 1-day change | +0.97% | +3.84% |
| YTD return | -32.72% | +38.07% |
| 1-year return | -29.53% | +97.59% |
| 5-year return | -47.97% | -41.83% |
| EPS (TTM) | $-2.17 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.03 | $6.50 |
| 52-week low | $12.42 | $2.86 |
| Distance from 52-week high | -37.39% | -8.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +144.58% | +108.91% |
| Average volume | 84.67K | 299.84K |
| Shares outstanding | 12.91M | 60.11M |
| Employees | 121 | 86 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Orchestra BioMed is about 2.2 times larger than MediWound by market value ($357.63M vs $161.89M).
- OBIO has outperformed MDWD by 127.1 percentage points over the past year.
About MediWound
MDWD stock →MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.
Health Care · Medicinal Chemicals and Botanical Products · 121 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
MDWD vs OBIO FAQ
Which is bigger, MediWound or Orchestra BioMed?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $357.63M compared with $161.89M for MediWound (MDWD).
Which stock has performed better over the past year, MDWD or OBIO?
OBIO returned +97.59% over the past 12 months, compared with -29.53% for MDWD (price return, excluding dividends). Past performance does not predict future results.
Are MediWound and Orchestra BioMed in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.